Table 1.

Criteria for mAbs prescription and discontinuation in the United Kingdom and Italy

	United Kingdom	Italy
Diagnosis	Episodic or chronic migraine with or without aura	Episodic or chronic migraine with or without aura
Minimum headache monthly frequency	≥ 4 days/month	≥ 8 days/month
Previous treatment failed	At least 3 of any migraine preventatives	At least 3 treatments including an antiepileptic, a tricyclic antidepressant and a beta-blocker. For chronic migraine one of the three mandatory drugs may be onabotulinum toxin A
Other criteria	Consider contraindications as per drug licence	- Consider contraindications as per drug licence - Migraine Disability Assessment (MIDAS) score ≥ 11
Criteria for treatment continuation	After 3 months of treatment: - 50% reduction of monthly migraine days in episodic migraine compared to baseline - 30% reduction of monthly migraine days in chronic migraine compared to baseline	After 3 months and 6 months of treatment: - 50% reduction of MIDAS score compared to baseline
Treatment discontinuation/pausing	- Not mandatory	- Mandatory after 12 (for fremanezumab and galcanezumab) or 13 injections (for erenumab)
Restarting criteria	- Patient has to fulfil baseline criteria	- Patient has to fulfil again baseline criteria

MIDAS Migraine Disability Assessment